Literature DB >> 29622080

Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer.

Girish S Shroff1, Patricia M de Groot1, Vassiliki A Papadimitrakopoulou2, Mylene T Truong1, Brett W Carter3.   

Abstract

The treatment strategy in advanced non-small cell lung cancer (NSCLC) has evolved from empirical chemotherapy to a personalized approach based on histology and molecular markers of primary tumors. Targeted therapies are directed at the products of oncogenic driver mutations. Immunotherapy facilitates the recognition of cancer as foreign by the host immune system, stimulates the immune system, and alleviates the inhibition that allows the growth and spread of cancer cells. The authors describes the role of targeted therapy and immunotherapy in the treatment of NSCLC, patterns of disease present on imaging studies, and immune-related adverse events encountered with immunotherapy.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunotherapy; Lung cancer; Targeted therapy

Mesh：

Year:  2018        PMID： 29622080     DOI： 10.1016/j.rcl.2018.01.012

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN： 0033-8389            Impact factor:   2.303


  29 in total

1.  Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Authors:  Lecia V Sequist; Jhanelle Elaine Gray; Wael A Harb; Ariel Lopez-Chavez; Robert C Doebele; Manuel R Modiano; David Michael Jackman; Maria Quintos Baggstrom; Akin Atmaca; Enriqueta Felip; Mariano Provencio; Manuel Cobo; Bambang Adiwijaya; Geoffrey Kuesters; Walid S Kamoun; Karen Andreas; J Marc Pipas; Sergio Santillana; Byoung Chul Cho; Keunchil Park; Frances A Shepherd
Journal:  Oncologist       Date:  2019-04-11

2.  Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma.

Authors:  Ming Li; Chuanying Li; Li Ke; Mali Zhan; Min Cheng
Journal:  Oncol Lett       Date:  2018-10-02       Impact factor: 2.967

3.  Patient, tumor, and healthcare factors associated with regional variability in lung cancer survival: a Spanish high-resolution population-based study.

Authors:  M Rodríguez-Barranco; E Salamanca-Fernández; M L Fajardo; E Bayo; Y-L Chang-Chan; J Expósito; C García; J Tallón; P Minicozzi; M Sant; D Petrova; M A Luque-Fernandez; M-J Sánchez
Journal:  Clin Transl Oncol       Date:  2018-10-19       Impact factor: 3.405

Review 4.  An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer.

Authors:  Tamkin Ahmadzada; Steven Kao; Glen Reid; Michael Boyer; Annabelle Mahar; Wendy A Cooper
Journal:  J Clin Med       Date:  2018-06-15       Impact factor: 4.241

5.  Myeloid-derived suppressor cells infiltration in non-small-cell lung cancer tumor and MAGE-A4 and NY-ESO-1 expression.

Authors:  Zhenbo Hou; Xiao Liang; Xinmei Wang; Ziqiang Zhou; Guilan Shi
Journal:  Oncol Lett       Date:  2020-03-31       Impact factor: 2.967

6.  Hsa_circ_0003998 promotes cell proliferation and invasion by targeting miR-326 in non-small cell lung cancer.

Authors:  Wanjun Yu; Hao Jiang; Huihui Zhang; Jipeng Li
Journal:  Onco Targets Ther       Date:  2018-09-07       Impact factor: 4.147

Review 7.  Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.

Authors:  S K Daniel; K M Sullivan; K P Labadie; V G Pillarisetty
Journal:  Clin Transl Med       Date:  2019-04-01

8.  The anti-tumor effect of taxifolin on lung cancer via suppressing stemness and epithelial-mesenchymal transition in vitro and oncogenesis in nude mice.

Authors:  Ronghua Wang; Xianjun Zhu; Qing Wang; Xiaoqing Li; Enling Wang; Qianqian Zhao; Qianqian Wang; Hongmei Cao
Journal:  Ann Transl Med       Date:  2020-05

9.  A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies.

Authors:  Dedong Cao; Huilin Xu; Ximing Xu; Tao Guo; Wei Ge
Journal:  Oncoimmunology       Date:  2018-08-20       Impact factor: 8.110

10.  The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases.

Authors:  Fabio Cofano; Matteo Monticelli; Marco Ajello; Francesco Zenga; Nicola Marengo; Giuseppe Di Perna; Roberto Altieri; Paola Cassoni; Luca Bertero; Antonio Melcarne; Fulvio Tartara; Alessandro Ducati; Diego Garbossa
Journal:  Cancer Control       Date:  2019 Jan-Dec       Impact factor: 3.302
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.